您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
发布时间: 2021 - 04 - 07
点击次数: 0
所属职位: 副总裁
所属公司: 上海医药集团股份有限公司
个人简介:
1973年7月出生。复旦大学高分子化学专业本科毕业,上海国家会计学院—上海财经大学联合培养会计专业(MPAcc)硕士。工程师、经济师。现为上海医药集团股份有限公司副总裁,并在本公司附属公司兼任董事等职务。曾任本公司战略与投资发展部总经理,上药中西总经理,上药东英总经理、上海津村制药董事长、上药新亚董事长、上药一生化董事长等职。
发布时间: 2021 - 04 - 07
点击次数: 0
所属职位: 生物制药资深顾问
所属公司: 生物制药资深顾问
个人简介:
徐炜先生是一位生物制药行业资深顾问和高管,拥有在美国、中国和欧洲工作经验。他获拥有国药集团的硕士学位和凯莱商学院的工商管理硕士学位。徐炜先生在信达生物担任高级副总裁期间,将PD-1和三个生物类似药从开发阶段推到成熟阶段并成功上市和商业化。在此之前,徐炜先生曾作为首席运营官加入舒迪安负责细胞治疗的运营。回国前,徐炜在美国知名制药公司工作,包括安近,百时美施贵宝和阿斯利康。  Wei is a biopharmaceutical industry executive with global experience in USA, China and Europe. He received his M.S. degree from Sino Pharm and MBA degree from Kelley School of Business. Wei worked as an SVP in Innovent Biologics and commercialized PD-1 and three biosimilars. Prior to that, Wei worked Sotio as a COO on cellular therapy projects. In USA, Wei worked in prominent pharmaceutical firms including Amgen, Bristol-Myers Squibb and AstraZeneca.
发布时间: 2021 - 04 - 07
点击次数: 0
所属职位: 大分子药学副总裁
所属公司: 再鼎医药
个人简介:
章博士(John Zhang)在生物医学科学和大分子抗体药学工艺技术研究有超过25年的工作经验。他不但在美国大学担任过教授,从事口腔肿瘤发生治疗方面教学与系统基础研究。并在美国的大型生物制药公司(Lonza, Altria and Bio-Techne )担任资生科学家与高级管理职位。 他在生物药制造工艺技术领域逐步建立了强大的能力并且知识面非常广博。            章博士在2016年1月受邀作为高级副总裁进入中国药企工作。他成功领导了齐鲁药业集团的工艺与生产团队,完成了多个仿制单克隆抗体项目工艺开发与生产以提供临床研究所需用药。其中负责的一个工艺验证项目已经成功地投入商业性生产。                     在2018-2020年期间,他去百济神州制药公司(BeiGene Ltd)为建立广州抗体工厂建设工艺团队的建设与早期自主研发项目的推进做出了重要贡献。  2020年7月,他加入了再鼎医药作为大分子药学副总裁,全面负责公司大分子药学。他负责公司大分子抗体工艺开发与担任再创苏州生物制药公司的企业负责人,组织实施生产运行,为公司自主研发研发项目提供临床用药。                由于章博士拥有广泛的生物药学方面的专业知识,所有工作的公司他都受邀提供药学相关专业知识与建议,对公司引进国外项目,提供十分重要的药学评估。Dr. Zhang (John Zhang) has more than 25 years of working experience in biomedical sciences and Biologics. Prior to his industrial tenure positions, he used to work as a professor in university (University of Illinois at Chicago) and engaged in systematic studies in the originals and treatment of oral tumors.  He also holds various senior management positions at large pharmaceutical companies in United States (Lonza, Altria and Bio-Techne).  He has gradually established strong capabilities in the field of biopharmaceutical manufacturing technology and has accumulated wide range of knowledge.  Dr. Zhang returned to work as a Sr. VP of Biologics for Chinese pharmaceutical company (Qilu Pharmaceutical Group) in Jan. 2016. He successfully led the teams working on process development and manufacturing operations. Under his leadership, multiple bio-similar mAb projects have been successfully approved for clinical studies. One of leading project under his directly engaging in PCS and PV has been successfully approved for commercial manufacturing in 2019.In 2018-2020, Dr. Zhang started his journey in Beigene Ltd as a VP of Manufacturing Technology. During his tenure at Beigene, Dr. Zhang made great contributions to the construction of BeiGene Manufacturing plant at early stage and the establishment of the Biologics CMC teams at Guangzhou Manufacturing factory. Meanwhile, he has been in charge of PD and Production team providing drug substances required for internal research projects at Suzhou Biologics Pilot Plant. In July 2020, he joined Zai Lab as a vice president of Biologics CMC, responsible for company's Biologics process development at Shanghai site and also a head of Suzhou Biologics Pilot plant responsible for DS & DP supply for clinical studies of company's internal research and development projects.               Due to his comprehensive knowledge in Biologics CMC, he has been invited to participate in the evaluations of most external Biologics projects potentially license-in for all companies he work for.
发布时间: 2021 - 04 - 07
点击次数: 0
所属职位: CEO
所属公司: 复星凯特生物科技公司
个人简介:
黄海先生 2020 年 12 月加入复星凯特生物科技有限公司担任 CEO。公司立足于自主研发和技术转移相结合,致力于肿瘤免疫细胞治疗技术(CAR-T/TCR-T)在中国的产业化和规范化,造福中国患者。 黄海先生在医药行业拥有近 25 年的丰富商业运营及国际化管理经验,曾先后在辉瑞、赛诺菲、罗氏诊断和美敦力等跨国药企任职。加入复星凯特前,担任辉瑞普强首席运营官(COO),曾在 2018 年打造了中国首个年销售额达 12 亿美元的单产品;并在带量采购的大环境下,积极发展公司未来战略,布局互联网医疗。
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务